A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7140 participants.
Also called NCT07241390
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,140 participants
- Sponsor
- Registry
-
NCT07241390 -
2025-523123-22-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Romania, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Tunisia, Türkiye, Ukraine, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07241390. Randomized; double masking; primary purpose treatment. Start 2025-12-01 (actual); primary completion 2031-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Condition
- Atherosclerosis Cardiovascular Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07241390- Content hash
9a5ffcb7d7ff6fff15763d26d283975d9e75fb75fd1ffaa143547d011d53cfd1